Zhang Jie, Yu Qianying, Peng Li, Lin Wenxia, Qin Yuesi, He Ying, Guo Jing, Xiao Min, Chen Mingling
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, Sichuan Province, P. R. China.
Medicine (Baltimore). 2020 Sep 25;99(39):e22400. doi: 10.1097/MD.0000000000022400.
Psoriasis is a chronic recurrent dermatological disease that patents always suffer from different comorbidities. Chinese herbal medicine (CHM) has been commonly used in the treatment of psoriasis for a long history. Previous systematic reviews (SRs)/meta-analyses (MAs) have shown that CHM may benefit patients with psoriasis. This overview aims to summarize the evidence from published SRs/MAs for clinical application and to provide several directions for future researches.
Nine electronic databases (Medline, Embase, Cochrane Library, AMED, CINAHL, CBM, CNKI, VIP Database, Wanfang Databases) will be searched from their inceptions to September 2020 without language restrictions. At least 2 reviewers will independently conduct the study selection, data extraction, and quality assessment. The methodological quality, risk of bias, reporting quality, and evidence quality will be respectively evaluated by the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR 2), the Risk of Bias in Systematic Reviews, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system.
The results of this overview will be submitted to a peer-reviewed journal for publication.
We expect to compile current evidence from published SRs/MAs of CHM for patients with psoriasis in an accessible and useful document.
This study is a protocol for an overview of SRs/MAs that did not involve individual data. Thus, ethical approval is not required.
DOI 10.17605/OSF.IO/VC654.
银屑病是一种慢性复发性皮肤病，患者常伴有不同的合并症。中药长期以来一直普遍用于治疗银屑病。以往的系统评价（SRs）/荟萃分析（MAs）表明，中药可能对银屑病患者有益。本概述旨在总结已发表的SRs/MAs中的证据以供临床应用，并为未来研究提供几个方向。
将检索九个电子数据库（Medline、Embase、Cochrane图书馆、AMED、CINAHL、CBM、CNKI、维普数据库、万方数据库），检索时间从建库至2020年9月，无语言限制。至少两名评审员将独立进行研究筛选、数据提取和质量评估。将分别通过系统评价方法学质量评估2（AMSTAR 2）、系统评价中的偏倚风险、系统评价和荟萃分析的首选报告项目（PRISMA）以及推荐分级、评估、制定和评价（GRADE）系统来评估方法学质量、偏倚风险、报告质量和证据质量。
本概述的结果将提交给同行评审期刊发表。
我们期望将已发表的关于中药治疗银屑病的SRs/MAs的现有证据汇编成一份易于获取且有用的文件。
本研究是一项关于SRs/MAs概述的方案，不涉及个体数据。因此，无需伦理批准。
OSF注册号：DOI 10.17605/OSF.IO/VC654。
